Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
University of Utah
Would you use CTS5 to help you decide whether to offer prolonged adjuvant ET to HR+ breast cancer?
Answer from: Medical Oncologist at Community Practice
I would
Sign in or Register to read more
5507
Related Questions
How would you approach surveillance imaging for men with early-stage, hormone receptor-positive breast cancer after unilateral mastectomy?
Would you offer adjuvant chemotherapy for triple negative invasive papillary carcinoma of breast?
Does pre-chemotherapy extent of nodal involvement impact your decision to offer adjuvant radiation in cN1, ypN0 triple-negative breast cancer?
Is there evidence supporting the adjuvant use of neratinib in patients with high-risk, hormone receptor–positive, HER2-negative breast cancer that harbors an activating HER2 mutation?
How do you approach the RxPonder data in premenopausal women with ER/PR+, HER2 negative, pN1, many of whom now qualify for CDK 4/6 inhibitors in adjuvant setting besides endocrine therapy (+/- OFS) if the RS 0-13 and 14-25?
Does delay to the time of lumpectomy impact your decision to omit radiation?
Do you hold endocrine therapy during adjuvant breast radiotherapy?
What is the best treatment approach to a patient with HGBCL with FISH translocation of BCL-6 and c-Myc given new classification of this entity?
What is your preferred method of surveillance after mastectomy?
Is the currently available data from INAVO sufficient to adopt this as a new standard of care for all patients or are you awaiting overall survival and/or PROs?